» Articles » PMID: 18474679

Developmental Changes in Human Liver CYP2D6 Expression

Overview
Specialty Pharmacology
Date 2008 May 14
PMID 18474679
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Within the human cytochrome P450 family, specific forms show developmental expression patterns that can affect drug clearance, efficacy, and safety. The objective of this study was to use dextromethorphan O-demethylase activity and quantitative Western blotting to identify CYP2D6 developmental expression patterns in a large (n = 222) and developmentally diverse set of pediatric liver samples. Immunodetectable levels of CYP2D6 protein determined for selected samples across all age categories showed a significant correlation with the corresponding dextromethorphan O-demethylase activity. Of gender, ethnicity, postmortem interval, and genotype, only increasing gestational age was associated with CYP2D6 activity and protein content in prenatal samples. In contrast, both age and genotype were associated with CYP2D6 expression in postnatal samples. CYP2D6 expression in liver samples from neonates less than 7 days of age was higher than that observed in first and second trimester samples, but not significantly higher than third trimester fetal samples. In contrast, expression in postnatal samples greater than 7 days of age was substantially higher than that for any earlier age category. Higher CYP2D6 expression also was observed in liver samples from Caucasians versus African Americans. Finally, using phenotype categories inferred from genotype, CYP2D6 activity was higher in postnatal samples predicted to be extensive or intermediate metabolizers versus poor metabolizers. These results suggest that age and genetic determinants of CYP2D6 expression constitute significant determinants of interindividual variability in CYP2D6-dependent metabolism during ontogeny.

Citing Articles

Current hPSC-derived liver organoids for toxicity testing: Cytochrome P450 enzymes and drug metabolism.

Kim H, Park H Toxicol Res. 2025; 41(2):105-121.

PMID: 40013078 PMC: 11850699. DOI: 10.1007/s43188-024-00275-8.


Pediatric flecainide pharmacogenomics: a roadmap to delivering precision-based care to pediatrics arrhythmias.

Palmen R, Walton M, Wagner J Front Pharmacol. 2025; 15:1477485.

PMID: 39741635 PMC: 11686437. DOI: 10.3389/fphar.2024.1477485.


Hypothermia as a Presenting Sign of Venlafaxine-Induced Neonatal Abstinence Syndrome in 2 Neonates.

Oswald M, El-Chaar G, Canter M J Pediatr Pharmacol Ther. 2024; 29(6):654-659.

PMID: 39659866 PMC: 11627578. DOI: 10.5863/1551-6776-29.6.654.


Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.

Walton M, Wagner J Genes (Basel). 2024; 15(3).

PMID: 38540438 PMC: 10969836. DOI: 10.3390/genes15030379.


Fetal and Infant Effects of Maternal Opioid Use during Pregnancy: A Literature Review including Clinical, Toxicological, Pharmacogenomic, and Epigenetic Aspects for Forensic Evaluation.

Giovannini E, Bonasoni M, Pascali J, Bini C, Pelletti G, Gualandi A Children (Basel). 2024; 11(3).

PMID: 38539313 PMC: 10969201. DOI: 10.3390/children11030278.